Akira Watanabe1, Norifumi Harimoto2, Takehiko Yokobori3, Kenichiro Araki1, Norio Kubo1, Takamichi Igarashi1, Mariko Tsukagoshi1, Norihiro Ishii1, Takahiro Yamanaka1, Tadashi Handa4, Tetsunari Oyama4, Tetsuya Higuchi5, Ken Shirabe1. 1. Department of Hepatobiliary and Pancreatic Surgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan. 2. Department of Hepatobiliary and Pancreatic Surgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan. nharimotoh1@gmail.com. 3. Research Program for Omics-Based Medical Science, Division of Integrated Oncology Research, Gunma University Initiative for Advanced Research (GIAR), 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan. 4. Department of Diagnostic Pathology, Gunma University, Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan. 5. Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Abstract
BACKGROUND: Liver resection is the most effective procedure for colorectal cancer liver metastasis (CRLM); however, early recurrence is an important problem that affects the postoperative prognoses of patients with CRLM. We previously suggested a therapeutic algorithm for CRLM using fluorodeoxyglucose-positron emission tomography (FDG-PET) and revealed the applicability of FDG-PET in predicting the prognosis after liver resection of CRLM. In this study, we assessed the correlation between FDG-PET and biological viability such as proliferation or metabolic activity. METHODS: We retrospectively evaluated 61 patients who underwent hepatectomy for CRLM. We assessed hypoxia inducible factor-1α (HIF-1α), pyruvate kinase isozyme M2 (PKM2), glucose transporter 1 (GLUT1), and Ki-67 expression via immunohistochemistry and evaluated the correlation between standardized uptake value (SUV) and these factors. RESULTS: High HIF-1α, PKM2, and GLUT1 expression were positively correlated with high SUV expression (P = 0.0444, 0.0296, and 0.0245, respectively). Ki-67 and SUV were also positively correlated (P = 0.00164). HIF-1α expression and PKM2 expression were significantly correlated (P = 0.0430), and PKM2 expression and GLUT1 expression were extremely significantly correlated (P < 0.0001). CONCLUSION: SUV reflected tumor proliferation or metabolic factors in CRLM. FDG-PET could be a useful modality for assessing tumor viability and may provide useful information regarding the appropriate treatment strategy for CRLM.
BACKGROUND: Liver resection is the most effective procedure for colorectal cancer liver metastasis (CRLM); however, early recurrence is an important problem that affects the postoperative prognoses of patients with CRLM. We previously suggested a therapeutic algorithm for CRLM using fluorodeoxyglucose-positron emission tomography (FDG-PET) and revealed the applicability of FDG-PET in predicting the prognosis after liver resection of CRLM. In this study, we assessed the correlation between FDG-PET and biological viability such as proliferation or metabolic activity. METHODS: We retrospectively evaluated 61 patients who underwent hepatectomy for CRLM. We assessed hypoxia inducible factor-1α (HIF-1α), pyruvate kinase isozyme M2 (PKM2), glucose transporter 1 (GLUT1), and Ki-67 expression via immunohistochemistry and evaluated the correlation between standardized uptake value (SUV) and these factors. RESULTS: High HIF-1α, PKM2, and GLUT1 expression were positively correlated with high SUV expression (P = 0.0444, 0.0296, and 0.0245, respectively). Ki-67 and SUV were also positively correlated (P = 0.00164). HIF-1α expression and PKM2 expression were significantly correlated (P = 0.0430), and PKM2 expression and GLUT1 expression were extremely significantly correlated (P < 0.0001). CONCLUSION: SUV reflected tumor proliferation or metabolic factors in CRLM. FDG-PET could be a useful modality for assessing tumor viability and may provide useful information regarding the appropriate treatment strategy for CRLM.
Authors: Reinhard Bos; Petra van der Groep; Astrid E Greijer; Avi Shvarts; Sybren Meijer; Herbert M Pinedo; Gregg L Semenza; Paul J van Diest; Elsken van der Wall Journal: Cancer Date: 2003-03-15 Impact factor: 6.860
Authors: Weibo Luo; Hongxia Hu; Ryan Chang; Jun Zhong; Matthew Knabel; Robert O'Meally; Robert N Cole; Akhilesh Pandey; Gregg L Semenza Journal: Cell Date: 2011-05-27 Impact factor: 41.582
Authors: Hooman Hosseini-Nik; Sandra E Fischer; Carol-Anne E Moulton; Gautam Karbhase; Ravi J Menezes; Steven Gallinger; Kartik S Jhaveri Journal: Abdom Radiol (NY) Date: 2016-02
Authors: Junichi Shindoh; Evelyne M Loyer; Scott Kopetz; Piyaporn Boonsirikamchai; Dipen M Maru; Yun Shin Chun; Giuseppe Zimmitti; Steven A Curley; Chusilp Charnsangavej; Thomas A Aloia; Jean-Nicolas Vauthey Journal: J Clin Oncol Date: 2012-11-13 Impact factor: 44.544
Authors: Monika Schindl; Sebastian F Schoppmann; Hellmut Samonigg; Hubert Hausmaninger; Werner Kwasny; Michael Gnant; Raimund Jakesz; Ernst Kubista; Peter Birner; Georg Oberhuber Journal: Clin Cancer Res Date: 2002-06 Impact factor: 12.531
Authors: Tina Binderup; Ulrich Peter Knigge; Birgitte Federspiel; Peter Sommer; Jane Preuss Hasselby; Annika Loft; Andreas Kjaer Journal: Diagnostics (Basel) Date: 2013-10-29